Dec 14 2021 Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option View
Dec 01 2021 Relmada Therapeutics to Present Data at the 60th Annual Meeting of the American College of Neuropsychopharmacology View
Nov 11 2021 Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results View
Nov 04 2021 Relmada Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021 View
Oct 29 2021 Relmada Therapeutics to Present Data at the Neuroscience Education Institute Congress View
Oct 04 2021 Relmada Therapeutics Provides Regulatory and Development Updates on Ongoing Late-Stage Clinical Program for REL-1017 for Treatment of Major Depressive Disorder View
Sep 17 2021 Relmada Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit View
